99 related articles for article (PubMed ID: 9272134)
1. Treatment for adult T-cell leukemia.
Hanada S; Utsunomiya A; Suzuki S; Uozumi K; Makino T; Arima T
Cancer Chemother Pharmacol; 1997; 40 Suppl():S47-50. PubMed ID: 9272134
[TBL] [Abstract][Full Text] [Related]
2. Clinical Features and Treatment Outcomes of 81 Patients with Aggressive Type Adult T-cell Leukemia-lymphoma at a Single Institution over a 7-year Period (2006-2012).
Kawano N; Yoshida S; Kuriyama T; Tahara Y; Yamashita K; Nagahiro Y; Kawano J; Koketsu H; Toyofuku A; Manabe T; Beppu K; Ono N; Himeji D; Yokota-Ikeda N; Inoue S; Ochiai H; Sonoda KH; Shimoda K; Ishikawa F; Ueda A
Intern Med; 2015; 54(12):1489-98. PubMed ID: 26073237
[TBL] [Abstract][Full Text] [Related]
3. Long-term maintenance combination chemotherapy with OPEC/MPEC (vincristine or methotrexate, prednisolone, etoposide and cyclophosphamide) or with daily oral etoposide and prednisolone can improve survival and quality of life in adult T-cell leukemia/lymphoma.
Matsushita K; Matsumoto T; Ohtsubo H; Fujiwara H; Imamura N; Hidaka S; Kukita T; Tei C; Matsumoto M; Arima N
Leuk Lymphoma; 1999 Dec; 36(1-2):67-75. PubMed ID: 10613451
[TBL] [Abstract][Full Text] [Related]
4. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes.
Bazarbachi A; Plumelle Y; Carlos Ramos J; Tortevoye P; Otrock Z; Taylor G; Gessain A; Harrington W; Panelatti G; Hermine O
J Clin Oncol; 2010 Sep; 28(27):4177-83. PubMed ID: 20585095
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of serum thymidine kinase in adult T-cell leukaemia and acute myeloid leukaemia.
Sadamori N; Ichiba M; Mine M; Hakariya S; Hayashibara T; Itoyama T; Nakamura H; Tomonaga M; Hayashi K
Br J Haematol; 1995 May; 90(1):100-5. PubMed ID: 7786770
[TBL] [Abstract][Full Text] [Related]
7. Effects of first-line chemotherapy on natural killer cells in adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
Ogura M; Ishida T; Tsukasaki K; Takahashi T; Utsunomiya A
Cancer Chemother Pharmacol; 2016 Jul; 78(1):199-207. PubMed ID: 27289375
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of chemotherapy-induced clinical remission in long survivors with aggressive adult T-cell leukemia/lymphoma.
Tsukasaki K; Ikeda S; Murata K; Maeda T; Atogami S; Sohda H; Momita S; Jubashi T; Yamada Y; Mine M
Leuk Res; 1993 Feb; 17(2):157-66. PubMed ID: 8429692
[TBL] [Abstract][Full Text] [Related]
9. EPOCH regimen as salvage therapy for adult T-cell leukemia-lymphoma.
Toriyama E; Imaizumi Y; Taniguchi H; Taguchi J; Nakashima J; Itonaga H; Sato S; Ando K; Sawayama Y; Hata T; Fukushima T; Miyazaki Y
Int J Hematol; 2018 Aug; 108(2):167-175. PubMed ID: 29651666
[TBL] [Abstract][Full Text] [Related]
10. Combination chemotherapy (RCM protocol: response-oriented cyclic multidrug protocol) for the acute or lymphoma type adult T-cell leukemia.
Uozumi K; Hanada S; Ohno N; Ishitsuka K; Shimotakahara S; Otsuka M; Chyuman Y; Nakahara K; Takeshita T; Kuwazuru Y
Leuk Lymphoma; 1995 Jul; 18(3-4):317-23. PubMed ID: 8535199
[TBL] [Abstract][Full Text] [Related]
11. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.
Kantarjian HM; O'Brien S; Smith TL; Cortes J; Giles FJ; Beran M; Pierce S; Huh Y; Andreeff M; Koller C; Ha CS; Keating MJ; Murphy S; Freireich EJ
J Clin Oncol; 2000 Feb; 18(3):547-61. PubMed ID: 10653870
[TBL] [Abstract][Full Text] [Related]
12. Major prognostic factors of adult patients with advanced T-cell lymphoma/leukemia.
Shimoyama M; Ota K; Kikuchi M; Yunoki K; Konda S; Takatsuki K; Ichimaru M; Tominaga S; Tsugane S; Minato K
J Clin Oncol; 1988 Jul; 6(7):1088-97. PubMed ID: 2899140
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of multidrug resistance protein in adult T-cell leukemia.
Ohno N; Tani A; Chen ZS; Uozumi K; Hanada S; Akiba S; Ren XQ; Furukawa T; Sumizawa T; Arima T; Akiyama SI
Clin Cancer Res; 2001 Oct; 7(10):3120-6. PubMed ID: 11595704
[TBL] [Abstract][Full Text] [Related]
14. Human T-cell leukemia virus type I Tax genotype analysis in Okinawa, the southernmost and remotest islands of Japan: Different distributions compared with mainland Japan and the potential value for the prognosis of aggressive adult T-cell leukemia/lymphoma.
Sakihama S; Saito M; Kuba-Miyara M; Tomoyose T; Taira N; Miyagi T; Hayashi M; Kinjo S; Nakachi S; Tedokon I; Nishi Y; Tamaki K; Morichika K; Uchihara JN; Morishima S; Karube KN; Tanaka Y; Masuzaki H; Fukushima T
Leuk Res; 2017 Oct; 61():18-24. PubMed ID: 28866351
[TBL] [Abstract][Full Text] [Related]
15. Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma.
Katsuya H; Yamanaka T; Ishitsuka K; Utsunomiya A; Sasaki H; Hanada S; Eto T; Moriuchi Y; Saburi Y; Miyahara M; Sueoka E; Uike N; Yoshida S; Yamashita K; Tsukasaki K; Suzushima H; Ohno Y; Matsuoka H; Jo T; Suzumiya J; Tamura K
J Clin Oncol; 2012 May; 30(14):1635-40. PubMed ID: 22473153
[TBL] [Abstract][Full Text] [Related]
16. A retrospective analysis of treatment outcomes in adult T cell leukemia/lymphoma patients with aggressive disease treated with or without allogeneic stem cell transplantation: A single-center experience.
Kawada H; Yoshimitsu M; Nakamura D; Arai A; Hayashida M; Kamada Y; Maekawa K; Fujino S; Arima M; Arima N; Tabuchi T; Inoue H; Hamda H; Suzuki S; Matsushita K; Arima N
Biol Blood Marrow Transplant; 2015 Apr; 21(4):696-700. PubMed ID: 25542158
[TBL] [Abstract][Full Text] [Related]
17. Adult T-cell leukemia-lymphoma.
Tsukasaki K
Hematology; 2012 Apr; 17 Suppl 1():S32-5. PubMed ID: 22507774
[TBL] [Abstract][Full Text] [Related]
18. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303.
Yamada Y; Tomonaga M; Fukuda H; Hanada S; Utsunomiya A; Tara M; Sano M; Ikeda S; Takatsuki K; Kozuru M; Araki K; Kawano F; Niimi M; Tobinai K; Hotta T; Shimoyama M
Br J Haematol; 2001 May; 113(2):375-82. PubMed ID: 11380402
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin's lymphoma treated with VEPA or VEPA-M.
Shimoyama M; Ota K; Kikuchi M; Yunoki K; Konda S; Takatsuki K; Ichimaru M; Ogawa M; Kimura I; Tominaga S
J Clin Oncol; 1988 Jan; 6(1):128-41. PubMed ID: 2891797
[TBL] [Abstract][Full Text] [Related]
20. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
Schmitz N; Kloess M; Reiser M; Berdel WE; Metzner B; Dorken B; Kneba M; Trumper L; Loeffler M; Pfreundschuh M; Glass B;
Cancer; 2006 Jan; 106(1):136-45. PubMed ID: 16331635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
